Email the author The Effect of Long-Acting Beta-2 Agonist Monotherapy and Long-Acting Anticholinergic Monotherapy to Quality-of-Life in Group B Stable COPD Patients
Abstract
Background: Based on the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD), treatment for group B stable COPD patients is a long-acting beta-2 agonist (LABA) or long-acting anticholinergic (LAMA). Some studies experienced that LAMA was better than LABA but the opposite was also found in several studies. COPD patients often experience a decline in physical activity which causes a decrease in quality of life. We aimed to compare the effect of LABA or LAMA on quality of life in group B stable COPD patients.
Methods: This was a study with case series design conducted on 50 COPD patients divided into two groups. The first group consisted of patients who used LABA for at least 3 months. The second group used LAMA for at least 3 months. All subjects filled in the SGRQ. The calculation of SGRQ was carried out using Microsoft Excel Calculator SGRQ.
Results: A total 41 men and 9 women were enrolled in this study. There was no significant difference between the use of indacaterol monotherapy and tiotropium monotherapy on the quality of life although tiotropium showed a better quality of life (76%) than indacaterol monotherapy (64%).
Conclusion: There was no significant difference in the use of indacaterol and tiotropium on the quality of life although in this case tiotropium showed better results (P=0.538).
Keywords
Full Text:
PDFReferences
Menteri Kesehatan Republik Indonesia. Pedoman Pengendalian Penyakit Paru Obstruktif Kronik. Keputusan Menteri Kesehatan Republik Indonesia, 1022/MENKES/SK/XI/2008 Indonesia; 2008 p. 4–39.
Perhimpunan Dokter Paru Indonesia. PPOK (Penyakit Paru Obstruktif Kronik): diagnosis dana Penetalaksanaan. 1st ed. Jakarta: UI-Press; 2016. 2 p.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 Report). Global Initiative for Chronic Obstructive Lung Disease. 2019.
World Health Organization. Chronic obstructive pulmonary disease (COPD) [Internet]. World Health Organization. 2017 [cited 2017 Oct 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
Jones R, Østrem A. Optimising pharmacological maintenance treatment for COPD in primary care. Prim Care Respir J. 2011;20(1):33–45.
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–55.
Gea J, Casadevall C, Pascual S, Orozco-Levi M, Barreiro E. Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction. J Thorac Dis. 2016;8(11):3379–400.
Flood P, Rathmell JP, Shafer S. Stoelting’s pharmacology and physiology in anesthetic practice. 5th ed. Philadelphia: Wolters Kluwer; 2015. 370–371 p.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal. 2017;49(3):1700214.
Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164.
Fukuchi Y. The aging lung and chronic obstructive pulmonary disease: similarity and difference. Proc Am Thorac Soc. 2009;6(7):570–2.
Soeroso NN, Zain-Hamid R, Sinaga BYM, Sadewa AH, Syafiuddin T, Syahruddin E, et al. The Role of CYP2A6 Genetic Polymorphism in Nicotine Dependence and Tobacco Consumption among Bataknese Male Smokers. Open Access Maced J Med Sci. 2018;6(5):864–6.
Broaddus VC, Mason RJ, Ernst JD, King TE, Lazarus SC, Murray JF, et al. COPD: clinical diagnosis and management. In: Murray & Nadel’s Textbook of Respiratory Medicine, 2-Volume Set. 6th ed. Canada: Elsevier; 2015. p. 767–85.
Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–67.
Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–88.
Gross NJ. Outcome measures for COPD treatments: a critical evaluation. COPD. 2004;1(1):41–57.
DOI: https://doi.org/10.36497/jri.v42i4.370
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Tri Setia Negara Sinulingga, Pandiaman Pandia, Amira P. Tarigan, Putri Chairani Eyanoer
INDEXING & PARTNER
| Jurnal Respirologi Indonesia pISSN: 0853-7704 - eISSN: 2620-3162 Address: Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia Phone: +62-21-2247-4845 Email: editor@jurnalrespirologi.org |  An official publication by the Indonesian Society of Respirology (ISR) |
 Creative Commons Attribution-NonCommercial 4.0 International License Statcounter |